Betabart (RV-01) — Initial data
2026
We remain focused on enrolling patients in the current cohort and look forward to reporting initial clinical data later this year,Source filing
RADX biotech catalysts & pipeline
RADIOPHARM THERANOSTICS LTD · Data as of 2026-09-08
Upcoming catalysts
RAD402 — Initial data
2H 2026
On track to share data from first two dose levels in 2H 2026Source filing
RAD101 — Topline data
Q4 2026
14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective).Source filing
RAD101 — FDA meeting
Oct 1
End-of-Phase 2 meeting with the U.S. FDA scheduled for October 1 st , 2026; on track to be Phase 3 ready by year-end 2026Source filing